Targeting the mammalian target of rapamycin pathway in osteosarcoma using combinative chemotherapy

Osteosarcoma is the most common primary malignant ＇bone sarcoma, and occurs predominantly in childrenand young adults. The overall survival of patients with osteosarcoma remains low at approximately 60%.1 The prognosis of osteosarcoma patients is highly associated with response to chemotherapy. Alth...

Full description

Saved in:
Bibliographic Details
Published inChinese medical journal Vol. 126; no. 10; pp. 1978 - 1981
Main Authors Liu, Pei-Yi, Zhang, Wei-Bin, Wei, Yi-Yong
Format Journal Article
LanguageEnglish
Published China Department of Orthopedics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Traumatology and Orthopedics, Shanghai 200025, China 20.05.2013
Subjects
Humans
Osteosarcoma - metabolism
Signal Transduction - physiology
TOR Serine-Threonine Kinases - metabolism
化疗
原发性
哺乳动物
患者
生存期
目标瞄准
雷帕霉素
骨肉瘤
mammalian target of rapamycin pathway
chemotherapy
osteosarcoma
Online AccessGet full text

Cover

More Information
Summary:Osteosarcoma is the most common primary malignant ＇bone sarcoma, and occurs predominantly in childrenand young adults. The overall survival of patients with osteosarcoma remains low at approximately 60%.1 The prognosis of osteosarcoma patients is highly associated with response to chemotherapy. Although multiple chemotherapy regimens have improved the outcome of patients with osteosarcoma, resistance to current regimens has been reported in more than 30% of patients,2 highlighting the need for novel, targeted therapies.
Bibliography:osteosarcoma; mammalian target of rapamycin pathway; chemotherapy.
11-2154/R
Osteosarcoma is the most common primary malignant ＇bone sarcoma, and occurs predominantly in childrenand young adults. The overall survival of patients with osteosarcoma remains low at approximately 60%.1 The prognosis of osteosarcoma patients is highly associated with response to chemotherapy. Although multiple chemotherapy regimens have improved the outcome of patients with osteosarcoma, resistance to current regimens has been reported in more than 30% of patients,2 highlighting the need for novel, targeted therapies.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0366-6999
2542-5641
DOI:10.3760/cma.j.issn.0366-6999.20112107